Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapyReview Article Published on 2023-09-062024-09-05 Journal: Bioactive Materials [Category] update2024, [키워드] Cancer immunosuppressive immunotherapeutic Nanocomposites tumor microenvironment [DOI] 10.1016/j.bioactmat.2023.08.022 PMC 바로가기 [Article Type] Review Article
Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature ReviewArticle Published on 2022-11-032022-11-15 Journal: Laboratory medicine [Category] 진단, [키워드] Acquired ADAMTS Anemia autoantibody Blood BNT162b2 BNT162b2 vaccine caplacizumab caused Complete COVID-19 COVID-19 vaccine deficiency Diagnosis gastrointestinal symptoms immunosuppressive literature microangiopathy MOST occurred outcome Patient patients Pfizer-BioNTech plasma positive Prednisone presenting report reported review second dose significantly the patient therapy thrombocytopenia thrombosis thrombotic Thrombotic thrombocytopenic purpura treated Treatment Vaccine was used [DOI] 10.1093/labmed/lmac016 PMC 바로가기
Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19Article Published on 2022-11-022022-11-15 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, [키워드] anti-Nucleocapsid IgG anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibody Antigen booster vaccination cellular cellular immunity Cohort Concentration convalescent COVID-19 detectable domain Endemic humoral IFN-γ IgG immune response Immunity Immunoglobulin Immunosuppressed Immunosuppression immunosuppressive individual liver Liver transplantation membrane nucleocapsid Prevalence protective immunity reactivity Receptor binding domain recipient remained retrieved robust SARS-CoV-2 significantly increased Spike protein stimulated T cell T cell response therapy vaccination [DOI] 10.1371/journal.pone.0276929 PMC 바로가기
Humoral and Cellular Immune Response to Covid-19 Vaccination in Patients with Chronic Graft-versus-Host Disease on ImmunosuppressionArticle Published on 2022-11-012022-11-15 Journal: Transplantation and cellular therapy [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome amplified anti-spike antibody antibody association cellular Characteristics chronic coronavirus COVID-19 COVID-19 vaccination demonstrated detect disease dose Efficacy enrolled Escalation evaluated group HCT humoral Humoral response immune immune response Immunosuppression immunosuppressive immunosuppressive therapy Infection initial management mononuclear cell natural infection neutralizing antibody Neutralizing antibody response neutralizing antibody titers Patient patient population patients Peripheral blood positive positive correlation present progression proportion Quantitative receiving Responder responders response Sample size SARS-CoV-2 sequence Significant statistical difference susceptibility T cell T cell receptor T cell response T cell responses the antibody response the patient therapy unique vaccination Vaccine was measured were measured worsened worsening [DOI] 10.1016/j.jtct.2022.08.026 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infectionResearch article Published on 2022-11-012022-10-05 Journal: Multiple sclerosis and related disorders [Category] 진단, [키워드] adjusted Admission admitted to ICU association Clinical outcome COVID-19 cross-sectional diagnosis of COVID-19 Disease-modifying therapies Electronic health record General population health systems Healthcare provider Hospital admission Hospitalization Hospitalized ICU immunomodulatory immunosuppressive in-hospital mortality increased risk Infection Iran Mortality mortality risk multiple sclerosis outcome Patient patients with COVID-19 PCR Result risk risk factor Severe COVID-19 Infection severity therapy vaccinated against COVID-19 were recorded [DOI] 10.1016/j.msard.2022.104067 [Article Type] Research article
Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric studyArticle Published on 2022-10-212022-11-15 Journal: Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome addition Analysis analyzed Antibody titer attenuate Baricitinib BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 vaccine Combination controls coronavirus coronavirus disease COVID-19 COVID-19 vaccine disease domain dose Glucocorticoids healthy volunteer humoral immune response immunomodulatory Immunosuppressant immunosuppressants immunosuppressive immunosuppressive agent Immunosuppressive medication impair inhibitor inhibitors interleukin-17 interleukin-6 investigated Japanese Kagawa methotrexate much lower Necrosis of BNT162b2 Outpatient Patient patients treated reduced rheumatic disease SARS-CoV-2 SARS-CoV-2 spike protein second dose serum serum antibody significantly significantly lower Spike protein the patient therapeutic agent Treatment university Vaccine [DOI] 10.1097/MD.0000000000031288 PMC 바로가기
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2Article Published on 2022-10-122022-11-16 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] activated T cell antibodies antibody Antibody Response booster booster dose booster vaccination CD137 CD69 CD8 T cell Cellular immune response ChAdOx1-S conducted decrease dose expressing expression Frequency humoral IFN-γ immune response immunosuppressive increase in indicated Infection Injections lack longitudinal analysis memory monocyte mRNA mRNA vaccine myeloid cell omicron participant PD-L1 peptides phenotype producing protective immunity reactive reduced SARS-CoV-2 SARS-CoV-2-specific T cell T cell T cell response T cells the spike protein TNF-α upregulation vaccination Vaccinations Vaccine variant vector vaccine virus-specific T cell [DOI] 10.3389/fimmu.2022.1012526 PMC 바로가기
SARS-CoV-2 in immunocompromised individualsArticle Published on 2022-10-112022-11-15 Journal: Immunity [Category] COVID19(2023년), SARS, 치료제, [키워드] adaptive anti-CD20 antiviral immune response B cell Cancer clearance Combination COVID-19 COVID-19 pandemic Critical Hematologic malignancy Immunity Immunocompromised immunocompromised individual immunologically immunosuppressive IMPROVE increased risk individual Infection Inflammation information limit morbidity and mortality populations provided SARS-CoV-2 T cell therapy Treatment treatment strategy underlying conditions understanding vaccination viral infection virus [DOI] 10.1016/j.immuni.2022.09.006 PMC 바로가기
Association between immunosuppressants and poor antibody responses to SARS-CoV-2 vaccines in patients with autoimmune liver diseasesArticle Published on 2022-10-052022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% CI 95% confidence interval acute respiratory syndrome addition adjusted odds ratio AEs All adverse event antibody Antibody Response Autoimmune autoimmune liver diseases B cell response BBIBP-CorV Chongqing comparable conducted confounders Control CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 vaccination flow cytometry groups HCs healthy healthy control higher risk immunogenicity Immunosuppressant immunosuppressants immunosuppressive inactivated incidence independent risk factor liver Liver disease memory B cell Mild NAb NAbs participant Patient patients physician Population Probability prospective observational study RBD reduced response Safe Safety SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2-specific B cell second severe acute respiratory syndrome coronavirus 2 significantly significantly lower Spike protein tested the receptor-binding domain the SARS-CoV-2 therapy university vaccination Vaccine Vaccines were recorded [DOI] 10.3389/fimmu.2022.988004 PMC 바로가기